#China #Hong Kong #Akeso #Cadonilimab #Ivonescimab

Akeso's Major Milestone: Inclusion of Cadonilimab and Ivonescimab in China’s NRDL

In a landmark move for enhanced patient care, Akeso, Inc., a trailblazer in biopharmaceutical innovation, has announced that two of its flagship bispecific antibody therapies, Cadonilimab and Ivonescimab, are to be included in China’s National Reimbursement Drug List (NRDL). This decision, effective January 1, 2025, enables broader access for patients suffering from specific types of cancer who require these advanced treatment options.

Innovation and Patients’ Needs

Cadonilimab, recognized as the world's first PD-1/CTLA-4 bispecific antibody, is celebrated for its dual action approach that effectively targets both pathways simultaneously, thus amplifying the immune response against tumors. It has been specifically approved for individuals with relapsed or metastatic cervical cancer who have not responded satisfactorily to initial platinum-based chemotherapy treatments. Preliminary clinical trials have shown a median overall survival of over 18 months among treated patients, a significant advancement considering the historically poor prognosis for this demographic.

On the other hand, Ivonescimab, the first PD-1/VEGF bispecific antibody globally, combines immunotherapy with anti-angiogenesis, showcasing remarkable efficacy in clinical trails. This therapy is aimed at patients suffering from non-small cell lung cancer (nsq-NSCLC) with EGFR mutations. Trials have indicated a 54% reduction in the risk of disease progression or mortality, setting a new benchmark in treatment regimens for advanced lung cancer.

The Broader Impact on Chinese Healthcare

China's NRDL plays a crucial role in determining which medications receive reimbursement under the country's extensive medical insurance system, which covers over 95% of its population. The inclusion of Cadonilimab and Ivonescimab marks a significant turning point for patients in need of effective cancer therapies, reducing their financial burden and often dire need for innovative treatments.

Dr. Xia Yu, the Founder and CEO of Akeso, emphasized the significance of this inclusion, stating, "It highlights the innovative and clinical importance of our groundbreaking biologics, thereby improving patient access to such vital treatments while alleviating financial pressures."

Future Prospects for Akeso

With over 50 innovative projects in various stages of development, Akeso is poised at the forefront of biopharmaceutical advancements. Both Cadonilimab and Ivonescimab are currently undergoing rigorous clinical trials, confirming their potential across a multitude of cancer types including gastric, liver, and pancreatic cancers.

Additionally, Akeso has spearheaded efforts such as Cadonilimab's recent approval for the first-line treatment of advanced gastric cancer, showcasing the company’s commitment to creating a diverse treatment portfolio that addresses numerous unmet medical needs.

The integration of these therapies within the NRDL is not merely a corporate triumph for Akeso; it represents a profound shift within China’s healthcare landscape, one that aligns with Akeso’s mission to elevate public health through innovative scientific breakthroughs.

Conclusion

As Akeso continues to champion scientific innovation, the inclusion of Cadonilimab and Ivonescimab on China’s National Reimbursement Drug List stands as a testament to the company's relentless pursuit of pioneering solutions in medicinal science. This milestone will undoubtedly enhance patient care and promote wider access to innovative life-saving treatments across the Chinese population. Akeso's multifaceted approach, combining research, development, and robust clinical trials, positions it as a leader in transforming the future of healthcare in oncology.

For further insights into Akeso’s developments and their impact, visit their website or follow them on LinkedIn and social platforms.